Search Clinical Trials in the EU

Duration

Visits

Safety phase (I)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

181-200 of 936 trials

Metastatic Castration-Resistant Prostate Cancer: Gedatolisib and Darolutamide Study

We are studying a new combination of gedatolisib and darolutamide for men with metastatic castration-resistant prostate cancer. The trial will evaluate safety, tolerability, and how well this treatment works.

Castration-Resistant Prostate Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncologyUrology

Advanced Breast Cancer: HER3-DXd Treatment Study

We are investigating a new drug for patients with inoperable advanced breast cancer who have progressed after previous treatment. The study aims to understand its safety and effectiveness, both alone and in combination with other therapies.

HER2-positive and HER2-low Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Diabetes Foot Ulcers: Mesenchymal Stem Cells Study

We are exploring whether mesenchymal stem cells can help heal foot ulcers in people with diabetes. This early study aims to assess the safety and potential benefits of this treatment.

Diabetic Foot Ulcer>2 yearsSafety phase (I)Efficacy phase (II)DermatologyDiabetology

Cervical Cancer: ITHACA Immunotherapy Study

We are investigating the safety and immune effects of a new immunotherapy for early-stage cervical cancer. This study aims to understand how well this treatment works when delivered near the tumor.

Cervical Cancer6-12 monthsSafety phase (I)Gynecology and ObstetricsOncology

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematology

Multiple Myeloma: BMS-986453 Treatment

We are testing a new drug for individuals with relapsed or refractory multiple myeloma. The goal is to understand its safety and how it may help manage their condition.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Small Cell Lung Cancer: BI 764532 with Chemotherapy

We are testing how well different doses of BI 764532 are tolerated by people with small cell lung cancer when combined with chemotherapy. This study aims to find the safest and most effective dose.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Small Cell Lung Cancer: BI 764532 Study

We are testing how well different doses of a new medication work with standard care for people with advanced small cell lung cancer. This study aims to see how well patients tolerate the treatment.

Extensive-Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Nebulized Fentanyl: Facial vs. Intranasal Delivery

We are comparing two ways to deliver nebulized fentanyl to healthy volunteers. This study aims to understand which method may be more effective for future use.

Healthy Volunteers1-2 yearsSafety phase (I)Internal MedicineOtolaryngologyPsychiatryPulmonology

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visits No Placebo Standard Medicines Partially RemotePsychiatry

Myelofibrosis: INCB057643 Safety Study

We are testing a new drug, INCB057643, for people with myelofibrosis and other advanced blood cancers. The study focuses on understanding its safety and how well patients tolerate it.

MyelofibrosisMyeloproliferative NeoplasmMyelodysplastic Syndrome>2 yearsSafety phase (I)Hematology

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteInternal MedicinePediatrics

Fluorescence Imaging in Crohn’s Disease and Psoriasis

We are exploring a new imaging technique to help diagnose and monitor Crohn’s disease and psoriasis. This study aims to see if it provides clearer insights into these conditions.

Crohn's DiseasePsoriasis1-2 yearsSafety phase (I)AllergologyDermatologyGastroenterology

Advanced Solid Tumors: VVD130037 Treatment

We are testing a new drug for patients with advanced solid tumors to see how safe it is and how well it may work against cancer. This study will help us understand its effects on the body and its potential benefits.

Solid TumorSquamous Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: ABBV-400 Treatment

We are evaluating a new treatment for individuals with advanced solid tumors to see how safe it is and if it may help improve their condition.

Locally Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No Placebo Cost ReimbursementOncology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Multiple Myeloma: Linvoseltamab Therapy Study

We are examining a new treatment called Linvoseltamab for adults with multiple myeloma that hasn't responded to standard care. The study looks at how it works with other cancer treatments.